Home » Stocks » AbbVie

AbbVie Inc. (ABBV)

Stock Price: $86.23 USD 0.32 (0.37%)
Updated Sep 25, 2020 4:02 PM EDT - Market closed
After-hours: $86.30 +0.07 (0.08%) Sep 25, 7:44 PM

Stock Price Chart

Key Info

Market Cap 152.18B
Revenue (ttm) 36.23B
Net Income (ttm) 6.96B
Shares Out 1.76B
EPS (ttm) 4.52
PE Ratio 19.08
Forward PE 7.07
Dividend $4.72
Dividend Yield 5.47%

Stock Quote

Trading Day Sep 25, 2020
Last Price $86.23
Previous Close $85.91
Change ($) 0.32
Change (%) 0.37%
Day's Open 85.98
Day's Range 85.46 - 86.86
Day's Volume 9,935,566
52-Week Range 62.55 - 101.28

More Stats

Market Cap 152.18B
Enterprise Value 233.57B
Earnings Date (est) Oct 30, 2020
Ex-Dividend Date Jul 14, 2020
Shares Outstanding 1.76B
Float 1.76B
EPS (basic) 4.72
EPS (diluted) 4.52
FCF / Share 8.57
Dividend $4.72
Dividend Yield 5.47%
Earnings Yield 5.24%
FCF Yield 9.28%
Payout Ratio n/a
Shares Short 13.28M
Short Ratio 1.82
Short % of Float 0.75%
Beta 0.72
PE Ratio 19.08
Forward PE 7.07
P/FCF Ratio 10.78
PS Ratio 4.20
PB Ratio 10.31
Revenue 36.23B
Operating Income 10.93B
Net Income 6.96B
Free Cash Flow 14.12B
Net Cash -81.39B
Net Cash / Share -46.12
Gross Margin 71.29%
Operating Margin 30.17%
Profit Margin 19.20%
FCF Margin 38.96%
ROA 8.23%
ROE 225.62%
ROIC 14.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (19)

Buy 13
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(27.57% upside)
Current: $86.23
Target: 110.00
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth1.57%16.08%10.06%12.16%14.52%6.23%2.23%5.37%11.55%-
Gross Profit25,82725,03521,17419,80618,35915,53414,20913,87212,80511,345
Operating Income12,9836,3839,5459,3407,5373,4115,6645,8173,6204,717
Net Income7,8825,6875,3095,9535,1441,7744,1285,2753,4334,178
Shares Outstanding1,4811,5411,5961,6221,6251,5951,5891,5771,577-
Earnings Per Share5.283.663.303.633.131.102.563.352.182.65
EPS Growth44.26%10.91%-9.09%15.97%184.55%-57.03%-23.58%53.67%-17.74%-
Dividend Per Share4.283.592.562.282.021.661.60---
Dividend Growth19.22%40.23%12.28%12.87%21.69%3.75%----
Operating Cash Flow13,32413,4279,9607,0417,5353,5496,2676,3456,2474,976
Capital Expenditures-552-638-529-479-532-612-491-333-356-448
Free Cash Flow12,77212,7899,4316,5627,0032,9375,7766,0125,8914,528
Cash & Equivalents39,9248,0619,7896,4238,4078,3749,8957,9766531,883
Total Debt66,72840,31037,36836,84231,67114,97714,72315,67248.00-
Net Cash / Debt-26,804-32,249-27,579-30,419-23,264-6,603-4,828-7,6966051,883
Book Value-8,172-8,4465,0974,6363,9451,7424,4923,36311,93215,703
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AbbVie Inc.
Country United States
Employees 47,000
CEO Richard A. Gonzalez

Stock Information

Ticker Symbol ABBV
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: ABBV


AbbVie discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.